Significant Collaboration Transactions - BiomEdit Narrative (Details) shares in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 30, 2022 USD ($) shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2023 USD ($) obligation shares	Dec. 31, 2023 USD ($) materialRight shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Zymergen purchase price consideration				$ 0	$ 19,912,000	$ 8,760,000
Loss on equity method investments				(2,635,000)	(43,761,000)	(77,284,000)
Equity method investments				0	1,543,000
Revenue remaining performance obligation amount				110,000,000.0	123,500,000
Deferred other income					222,600,000	189,200,000
Revenue recognized				$ 251,455,000	477,706,000	313,837,000
BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Zymergen purchase price consideration	$ 32,500,000		$ 4,000,000
Common units (in shares) | shares	3.9
Shares forfeited (in shares) | shares	0.7
Additional preferred units issued (in shares) | shares			0.8
BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of material rights | materialRight				4
Allocated upfront non-cash consideration				$ 2,200,000
Additional non-cash consideration			$ 1,100,000
Revenue from contract with customer, number of performance obligations | obligation			4
Revenue remaining performance obligation amount			$ 300,000
Deferred other income				7,700,000	8,100,000
Revenue recognized				$ 2,200,000	1,000,000.0
BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common units (in shares) | shares				0.7
Shares forfeited (in shares) | shares				0.3
Loss on equity method investments				$ (1,461,000)	(8,503,000)	$ 0
Equity method investments	$ 8,900,000			$ 0	369,000
Common unit, outstanding (in shares) | shares				0.4
Series A Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares sold (in shares) | shares		1.8
Total Zymergen purchase price consideration		$ 19,500,000			$ 57,100,000
Additional preferred units sold (in shares) | shares		7.2					5.4
Series A Preferred Stock | BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares sold (in shares) | shares	6.7
Additional preferred units sold (in shares) | shares	1.5
Series A Preferred Stock | BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loss on equity method investments				$ 1,500,000
Allocated upfront non-cash consideration				$ 1,100,000